- Home
- NTHI vs ISPR Comparison
NTHI vs ISPR Comparison
Compare NTHI & ISPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTHI | ISPR |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.5M | 89.0M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NTHI | ISPR |
|---|---|---|
| Price | $4.23 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $7.50 |
| AVG Volume (30 Days) | ★ 180.6K | 26.2K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $39,990.00 | ★ $127,494,304.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.01 | $1.01 |
| 52 Week High | $12.99 | $3.87 |
Technical Indicators
Market Signals| Indicator | NTHI | ISPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 55.19 |
| Support Level | $3.01 | $1.55 |
| Resistance Level | $4.59 | $1.98 |
| Average True Range (ATR) | 0.44 | 0.17 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 58.70 | 70.92 |
Price Performance
Historical ComparisonAbout NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.